Ranjana Kadle, Ph.D.
Senior Associate
DIRECT: 716-848-1628
rkadle@hodgsonruss.com

HodgsonRuss
ATTORNEYS • LLP

August 31, 2001

Assistant Commissioner for Patents
Box: PCT
Washington, D.C. 20231

EXPRESS MAIL NO. ET170405380US
DATE OF DEPOSIT: AUGUST 31, 2001

Re: Entry into the United States National Phase
International Patent Application No. PCT/GB00/00760

Dear Sir:

Enclosed for filing for entering the national stage under 35 USC 371 is a check for $511.00 for payment of the basic national fee (USPTO was neither ISA nor IPEA - Search Report prepared by European Patent Office) plus fee for 9 (nine) additional dependent claims, together with a copy of the International Application in English. Please note that the filing fee has been calculated based on the claims as amended in the enclosed Preliminary Amendment. Please also note that the applicant is entitled to small entity status.

Also enclosed are copies of the International Search report and the International Preliminary Examination Report. The Declaration and Power of Attorney will be filed at a later date.

If there is any deficiency in the basic national fee or processing fees at this time or during the pendency of this application, please charge such deficiency, or credit any overpayment, to Deposit Account No. 08-2442 of applicant's attorneys. A duplicate of this letter is enclosed for that purpose.

Respectfully,

Ranjana Kadle
Reg. No. 40,041

/mms
Enc.
BFLODOCS:589425_1 (CMSX01)

Express Mail No. ET170405380US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: James et al.
Serial No.: Not yet assigned; based on PCT/GB00/00760
Filed: Herewith (8/31/01)
For: Culture of Mycobacteria

Preliminary Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants respectfully request that the sapplication being filed herewith be amended as follows.

Paragraph beginning on line 5, page 4

Accordingly, a first aspect of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of at least 0.1% (v/v) detergent. Sufficient detergent is present so that a substantially homogenous suspension of cells is maintained.

Paragraph beginning on line 10, page 4

Preferably, the method of the invention comprises growing said mycobacteria in batch fermenter culture or continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1.0 percent, at a pH of 6.9 +/- 0.9 [and with agitation in the presence of sufficient detergent to maintain a substantially homogenous suspension of single cells].

Paragraph beginning on line 4, page 8

The invention further provides, in a second aspect, a growth medium for culture of mycobacteria, comprising:

a carbon source;

a mitogen;

trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
at least 0.1% (v/v) detergent.

Paragraph beginning on line 29, page 8

Thus, a particularly preferred embodiment of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation in the presence of at least 0.1% (v/v) [sufficient] detergent so that a substantially homogenous suspension of single cells is maintained, and in the presence of a growth medium according to combination of the above-described media.

Please amend the claims as follows.

1. (Amended) A method of culture of mycobacteria other than *M. avium*, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of [sufficient detergent so that a substantially homogenous suspension of cells is maintained] at least 0.1% (v/v) detergent.

Please cancel claim 2.

3. (Amended) A method according to Claim 1 [or 2], comprising culturing the mycobacteria at a temperature or 35°C +/- 10°C.

4. (Amended) A method according to [any of Claims 1 to 3] Claim 1, comprising maintaining the pH at 6.9 +/- 0.9.

5. (Amended) A method according to [any of Claims 1 to 4] Claim 1, comprising culturing the mycobacteria with an initial dissolved oxygen concentration of at least 1% (v/v) air saturation.

6. (Amended) A method according to [any of Claims 1 to 5] Claim 1, for culture of mycobacteria selected from *M. tuberculosis, M. bovis* and *M. vaccae*.

7. (Amended) A method according to [any of Claims 1 to 6] Claim 1 for batch culture of mycobacteria, wherein detergent is present at from 0.1 to 1.0% (v/v).

8. A method according to Claim 7, wherein detergent is present at about 0.2% (v/v).

9. (Amended) A method according to [any of Claims 1 to 6] Claim 1 for continuous culture of mycobacteria, wherein detergent is present at at least 0.1% (v/v).

10. A method according to Claim 9, wherein detergent is present at at least 0.15% (v/v).

11. (Amended) A method according to Claim 9 [or 10], wherein the culture is carried out continuously with a dilution rate of at least 0.02 h^{-1}.

12. A method according to Claim 11, wherein the culture is carried out continuously with a dilution rate of at least 0.025 h^{-1}.

13. (Amended) A method [of culture of mycobacteria] according to Claim 9, comprising growing said mycobacteria in continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1 percent, at a pH of 6.9 +/- 0.9, at a dilution rate of at least 0.02 h^{-1} [and with agitation in the presence of sufficient detergent to maintain a substantially homogenous suspension of single cells].

14. (Amended) A growth medium for culture of mycobacteria, comprising:

a carbon source;

a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
greater than 0.1% (v/v) detergent.

15. A growth medium according to Claim 14, wherein the carbon source is selected from glucose, glycerol and an amino acid.

16. (Amended) A growth medium according to Claim 14 [or 15], wherein the mitogen is asparagine.

17. (Amended) A growth medium according to [any of Claims 14 to 16] Claim 14, comprising trace elements selected from Ca, Mg, Zn, Co, Cu, Mn, Ni, Fe, K, and mixtures thereof.

18. (Amended) A growth medium according to [any of Claims 14 to 17] Claim 14, wherein the nitrogen source is selected from an amino acid and an ammonium salt.

19. (Amended) A growth medium according to Claim 18, comprising an amino acid component selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and mixtures thereof.

20. (Amended) A growth medium according to [any of Claims 14 to 19] Claim 14, further comprising a vitamin/co-factor component selected from inositol, thiamine, calcium pantothenate, co-enzyme A, nicotinamide, biotin, DL-thiocitic acid, and mixtures thereof.

21. (Amended) A growth medium according to [any of Claims 14 to 20] Claim 14, further comprising one or more components selected from sodium hydroxide, glutathione, glycerol, haemin, sodium pyruvate and ∝-ketoglutarate.

22. (Amended) A method [of culture of mycobacteria] according to Claim 1, comprising culturing said mycobacteria[, in batch or continuous culture, with agitation in the presence of sufficient detergent so that a substantially homogenous suspension of single cells is maintained, and] in the presence of a growth medium [according to any of Claims 14 to 22.] comprising:

a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
greater than 0.1% (v/v) detergent.

Please cancel claims 23 and 24.

25. (Amended) A method of culture of a mycobacteriophage, comprising culture of mycobacteria according to [any of Claims 1-13, 22 or 23] Claim 1, and contacting said mycobacteria with a mycobacteriophage.

26. A method according to Claim 25, comprising challenging the mycobacteria with an agent for promoting and/or assisting mycobacteriophage adsorption on the mycobacteria.

27. (Amended) A method according to Claim [25] 26, wherein challenge occurs prior to or substantially at the same time as contacting the mycobacteria with the mycobacteriophage.

28. (Amended) A method according to [any of Claims 25-27] Claim 25, comprising reducing or minimising exposures of the phage to detergent present in the mycobacteria culture medium.

29. (Amended) A method according to Claim 28, comprising allowing phage infection to be established, and then increasing the detergent concentration to an amount sufficient to at least 0.1% (v/v) detergent.

Clean versions of the amended specification and claims is enclosed.

Please charge any fee due to Deposit Account No. 08-2442.

Respectfully submitted,
HODGSON RUSS LLP

By _____
Ranjana Kadle,
Registration No. 40,041

One M & T Plaza, Suite 2000
Buffalo, NY 14203
Tel (716) 848-1628
August 31, 2001
BFLODOCS:587889_1 (CLM901)

CLEAN VERSION OF THE AMENDED SPECIFICATION

Paragraphs starting on line 5, page 4

Accordingly, a first aspect of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of at least 0.1% (v/v) detergent. Sufficient detergent is present so that a substantially homogenous suspension of cells is maintained.

Paragraph starting on line 10, page 4

Preferably, the method of the invention comprises growing said mycobacteria in batch fermenter culture or continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1.0 percent, at a pH of 6.9 +/- 0.9.

Paragraphs beginning on lines 4, page 8

The invention further provides, in a second aspect, a growth medium for culture of mycobacteria, comprising:

a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
at least 0.1% (v/v) detergent.

Paragraph beginning on line 29, page 8

Thus, a particularly preferred embodiment of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation in the presence of at least 0.1% (v/v) detergent detergent so that a substantially homogenous suspension of single cells is maintained, and in the presence of a growth medium according to combination of the above-described media.

CLEAN VERSION OF AMENDED CLAIMS

1. (Amended) A method of culture of mycobacteria other than *M. avium*, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of at least 0.1% (v/v) detergent.

2. Deleted.

3. (Amended) A method according to Claim 1, comprising culturing the mycobacteria at a temperature or 35°C +/- 10°C.

4. (Amended) A method according to Claim 1, comprising maintaining the pH at 6.9 +/- 0.9.

5. (Amended) A method according to Claim 1, comprising culturing the mycobacteria with an initial dissolved oxygen concentration of at least 1% (v/v) air saturation.

6. (Amended) A method according to Claim 1, for culture of mycobacteria selected from *M. tuberculosis, M. bovis* and *M. vaccae*.

7. (Amended) A method according to Claim 1 for batch culture of mycobacteria, wherein detergent is present at from 0.1 to 1.0% (v/v).

8. A method according to Claim 7, wherein detergent is present at about 0.2% (v/v).

9. (Amended) A method according to Claim 1 for continuous culture of mycobacteria, wherein detergent is present at at least 0.1% (v/v).

10. A method according to Claim 9, wherein detergent is present at at least 0.15% (v/v).

11. (Amended) A method according to Claim 9, wherein the culture is carried out continuously with a dilution rate of at least 0.02 h^{-1}.

12. A method according to Claim 11, wherein the culture is carried out continuously with a dilution rate of at least 0.025 h^{-1}.

13. (Amended) A method according to Claim 9, comprising growing said mycobacteria in continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1 percent, at a pH of 6.9 +/- 0.9, at a dilution rate of at least 0.02 h^{-1}.

14. (Amended) A growth medium for culture of mycobacteria, comprising:

a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
greater than 0.1% (v/v) detergent.

15. A growth medium according to Claim 14, wherein the carbon source is selected from glucose, glycerol and an amino acid.

16. (Amended) A growth medium according to Claim 14, wherein the mitogen is asparagine.

17. (Amended) A growth medium according to Claim 14, comprising trace elements selected from Ca, Mg, Zn, Co, Cu, Mn, Ni, Fe, K, and mixtures thereof.

18. (Amended) A growth medium according to Claim 14, wherein the nitrogen source is selected from an amino acid and an ammonium salt.

19. (Amended) A growth medium according to Claim 18,

comprising an amino acid component selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and mixtures thereof.

20. (Amended) A growth medium according to Claim 14, further comprising a vitamin/co-factor component selected from inositol, thiamine, calcium pantothenate, co-enzyme A, nicotinamide, biotin, DL-thiocitic acid, and mixtures thereof.

21. (Amended) A growth medium according to Claim 14, further comprising one or more components selected from sodium hydroxide, glutathione, glycerol, haemin, sodium pyruvate and ∝-ketoglutarate.

22. (Amended) A method according to Claim 1, comprising culturing said mycobacteria in the presence of a growth medium comprising:

a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
greater than 0.1% (v/v) detergent.

23. (Deleted)

24. (Deleted)

25. (Amended) A method of culture of a mycobacteriophage, comprising culture of mycobacteria according to Claim 1, and contacting said mycobacteria with a mycobacteriophage.

26. A method according to Claim 25, comprising challenging the mycobacteria with an agent for promoting and/or assisting mycobacteriophage adsorption on the mycobacteria.

27. (Amended) A method according to Claim 26, wherein challenge occurs prior to or substantially at the same time as contacting the mycobacteria with the mycobacteriophage.

28. (Amended) A method according to Claim 25, comprising reducing or minimising exposures of the phage to detergent present in the mycobacteria culture medium.

29. (Amended) A method according to Claim 28, comprising allowing phage infection to be established, and then increasing the detergent concentration to an amount sufficient to at least 0.1% (v/v) detergent.

CULTURE OF MYCOBACTERIA

The present invention relates to a method of culture of mycobacteria, to a growth medium therefor, and to a method of culture of mycobacteriophage.

Health risks associated with mycobacteria have been known for many years and diseases caused by some species are responsible for major global healthcare problems.

The emergence of antibiotic resistant strains of Mycobacteria responsible for tuberculosis (TB) have led to increasing numbers of deaths in those contracting the infection. A TB vaccine based on an attenuated strain of *M.bovis* (BCG) has been available for several years, but protection is restricted to particular ethnic groups, for reasons that are unknown. Mycobacteria have also been associated with several other conditions such as Crohn's Disease.

In addition, there are indications that inoculation with products derived from some mycobacterium species can mediate changes in immune responses which have beneficial effects. Thus, products of this type are currently undergoing evaluation to investigate their therapeutic usefulness against a range of conditions, including TB and cancers.

A major problem associated with the study and production of pharmaceutical products based on mycobacteria is the difficulty associated with bacterial growth. Conventional methods involve growth on solid agar slopes and, consequently, manufacturing products using this type of approach is both labour intensive and costly. These processes are poorly defined leading to batch variation.

Development of improved culture processes have made only limited progress with problems of relatively slow growth rate and bacterial aggregation. Batch culture processes have been associated with apparent loss of virulence, and/or essential components.

The majority of studies to date have grown *M.tuberculosis* as surface pellicles or as agitated dispersed cultures over long periods. Media used have been relatively simple containing a carbon source, nitrogen and buffered salts together with trace elements and were designed to provide high yields free of macromolecular medium components. Glycerol is considered the essential carbon source to ensure copious growth.

Media for culture of tubercle bacilli is described by Dupos *et al* in AM.REV.TUBERC. volume 56, 1947, pp334-345. A growth medium referred to as "Tween®-albumin" medium was used, containing 0.01-0.05 percent Tween® 80 and from 0.5-1.0 percent albumin. This growth medium has hitherto been the standard growth medium used in this field. Wayne L.G. in Infection and Immunity, Sept.1977, pp528-530 used this same medium and reported a mean generation time of 17-18 hours for *Mycobacterium tuberculosis*. Lowrie *et al*, in Journal of General Microbiology, Volume 110, 1979, pp431-441 used a concentrated version of the same medium. A review by Wayne L.G in Tuberculosis: Pathogenesis, Protection, and Control, published by the American Society for Microbiology in 1994, pp73-83 also describes how most published work in this area has employed 0.02 percent Tween® 80 and 0.5 percent bovine serum albumin, the albumin being used to protect the bacillus from toxic effects of traces of oleate released from the Tween® 80. Youmans and Youmans reported in 1959 that 0.05 per cent Tween® 80 slowed mycobacterial growth noticeably.

Another problem with existing culture methods and culture media is that the mean generation time, or doubling time, of the bacillus is rather long. For commercial production of mycobacteria it would be desirable to reduce the doubling time so that a greater yield of bacillus and bacillus products, such as enzymes, may be obtained. Typically, it is found that a culture period of at least two or three weeks is necessary before the culture may be harvested to yield any useable volume of products.

Wayne L.G, who has published widely in this area, has reported that growth of

mycobacteria in detergent-containing medium results in diminution of virulence, which is a serious disadvantage.

It is also found that the existing culture methods of mycobacteria produce rather low yields. Lowrie *et al* obtained yields of around $8x10^8$ bacteria ml^{-1}, but only at very low dilution rates of $0.016h^{-1}$, indicating a doubling time of about 43 hours. Wayne describes a culture having a quicker doubling time, but only at cell densities in the region of $4x10^7$ CFU ml^{-1}. It would accordingly be desirable to provide a culture having a reduced doubling time whilst maintaining high bacterial densities.

It is desirable to produce mycobacteria at increased yields. Whilst the maintainance of bacterial virulence is desirable for the purpose of vaccine preparations, the production of avirulent bacteria possessing virulent surface epitopes is also desirable for vaccine preparation. High yields of BCG mycobacteria would be particularly useful in manufacture of the BCG vaccine. Currently, vaccine components are made using many hundreds or even thousands of individual flasks. This is highly inefficient, with batch to batch variation, but continuous culture methods or large scale fermenter culture are not available to replace this inefficient method.

An objective of the present invention is to provide for batch or continuous culture of mycobacteria, in particular continuous culture that will maintain bacterial virulence (or avirulent bacteria possessing virulent cell surface epitopes), and provide cells of defined and consistent properties. Another objective is to provide a growth medium for culture of mycobacteria.

As mentioned above, conventional culture methods have achieved relatively poor yields of mycobacteria. This, in turn, has meant that high yield mycobacteriophage culture methods have proved problematic. In this respect, conventional solid phase preparation methods inherently produce limited phage yields, whereas conventional liquid phase yields are dependent on *inter alia* the

concentration of mycobacterial host available in the culture medium. Thus, a further objective of the present invention is to provide a method of culturing mycobacteriophage which overcomes/alleviates the prior art poor yield problems.

Accordingly, a first aspect of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of at least 0.1% (v/v) detergent. Sufficient detergent is present so that a substantially homogenous suspension of cells is maintained.

Preferably, the method of the invention comprises growing said mycobacteria in batch fermenter culture or continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1.0 percent, at a pH of 6.9 +/- 0.9.

In use of the present invention, illustrated by specific embodiments described below in more detail, and using *Mycobacteria tuberculosis*, we have developed a method which allows high yields of bacteria from both batch and continuous culture systems. Further, we have shown that mycobacteria generated using the methods of embodiments of the present inventions are highly virulent as demonstrated in a standard guinea pig infection model of *M.tuberculosis*. Indeed, potency of *Mycobacteria tuberculosis* grown using these methods is comparable with *M.tuberculosis* grown using the solid agar slope method.

In a specific embodiment of the present invention, growth of *M.tuberculosis* in steady-state continuous culture achieved a biomass yield of $1.2gl^{-1}$ cell dry weight. Cells grown in this continuous culture, and also in batch culture, displayed virulence comparable to cells grown on Middlebrook agar slopes, strongly indicating the suitability of these methods for growth of mycobacteria spp, such as *M. tuberculosis* or *M. bovis*, for prolonged periods in chemostat culture.

It is thus an advantage that the method of the invention enables growth at

increased cell densities and with reduced mean generation times, or doubling times. It is further of advantage that using the method of the present invention expression of virulence determinants has been maintained. Thus, the method is of application for production of mycobacteria such as for incorporation into BCG vaccines.

In the present invention, the term "batch culture" is used in its conventional sense to refer to a fixed volume of culture medium which is inoculated with a micro-organism. After a period of adjustment, termed the lag phase, the organism starts to grow and multiply reaching the maximum growth rate possible in that environment – termed exponential growth. After multiple generations essential nutrients become depleted or toxic metabolites build-up causing growth to slow and eventually cease. This is a closed system and the environment is constantly changing as the organism grows. This type of culture is typically performed in shake flasks, 50–500 ml, where only temperature is controlled though in embodiments of the invention temperature, pH and oxygen have been controlled. A further benefit of methods of the invention is that through control of environmental parameters there is reduced batch-to-batch variation, leading to cultures of more consistent composition and less bacterial heterogeneity, which is a significant consideration during production of vaccine components from these cultures.

The term "fermenter culture" is similarly used with reference to a type of batch culture operated with more control over the environmental parameters such as pH and aeration. Fermenters are normally used for production, hence the culture volume is larger.

The term "continuous culture" is used to refer typically to a culture of constant volume to which medium is added continuously and from which there is continuous removal of any overflow culture. By adding growth components in the fresh medium, the organism continues to multiply. When this system reaches equilibrium, cell number and nutrient status remain constant, it is said to be in

steady state.

Lastly, the term "chemostat culture" refers to the current most common type of continuous culture device. Two elements are generally used to control the culture, the concentration of an essential nutrient, such as carbon source, and the flow rate. After inoculation the culture grows until an essential nutrient becomes depleted and limits growth, however, the continuous addition of fresh medium containing the limiting nutrient permits continued growth. The cell density is controlled by the concentration of limiting nutrient added. The limiting nutrient can be altered by manipulating the medium formulation. The rate of medium addition controls the growth rate (generation time) of the culture.

In the method of the invention, it is preferred that the culture temperature is maintained at 35°C +/- 10°C, more preferably 35°C +/- 5°C, and in specific embodiments of the invention this preferred temperature has been maintained for in excess of three weeks with continuous mycobacteria growth. The pH of the culture medium, in continuous operation, is typically controlled to within +/- 0.9 of pH 6.9, more preferably +/- 0.5 of pH 6.9. pH may be controlled using addition of acid or alkaline solution to the culture medium, according to the pH correction required. In specific embodiments of the invention described below, sodium hydroxide at a concentration of 0.5M and sulphuric acid at a concentration of 0.5M is used. The dissolved oxygen concentration of the culture is typically at an initial level of at least 40% (v/v) air saturation, preferably at least 50%.

Detergent is present in the method of the invention as a dispersing agent to maintain a high proportion of the mycobacteria suspended in a substantially homogenous suspension, preferably as single cells or small clumps containing 2 to 10 bacilli, preferably 2 to 5 bacilli. In one embodiment, at least 50%, preferably at least 75%, particularly preferably at least 90% of the total mycobacterial cell weight is suspended as above.

Once thus dispersed, cells can grow in an environment enabling higher growth

rates under relatively constant and controlled conditions. It is possible, though the applicant does not wish to be bound by any theory, that once mycobacteria form pellicles as in previous culture methods they can not thereafter be dispersed - the invention may thus improve the previous methods by preventing or reducing loss of bacilli into such pellicles. Some detergents in use slowly release toxic components into the culture medium, so the amount of detergent present should not be so high as to risk the detergent or any of its components reaching toxic levels. Similarly, excess detergent can lead to foaming of the culture and should be avoided. The level of detergent may suitably be at least 0.1% (v/v).

Anionic detergents are preferred, in particular esters of sorbitan and derivatives thereof, though it is believed that the advantageous effects of the invention and the results obtained in the specific embodiments may likewise be realised using any of a wide range of detergents. Particularly good results have been obtained using a polyethane-diyl derivative of a sorbitan ester, namely Tween® 80, other such esters being Tween® 20, Tween® 40 and Tween® 60. Despite the presence of detergent it has been found that albumin may be omitted from the growth medium without slowing mycobacterial growth.

In use of the methods of the invention for batch culture of mycobacteria, detergent may be present at from 0.1 to 1.0 % (v/v), more preferably from 0.1 to 0.5 %, most preferably about 0.2 % (v/v).

In use of the methods of the invention for continuous culture of mycobacteria, detergent may be present at least 0.1 % (v/v), more preferably at least 0.15 % (v/v), and most preferably about 0.2%, its level further preferably being no more than 1.0%, and usually no more than 0.7%. When the culture is being operated continuously, medium is continuously introduced into the culture, the rate of introduction expressed as a dilution rate. The culture of the invention can be carried out continuously with a dilution rate of at least 0.02 h^{-1}, resulting in a high yield of bacteria, and these bacteria have been found to have preserved their virulence. A dilution rate of at least 0.025 h^{-1} can also be sustained, and in a

specific embodiment a dilution rate of about 0.03 h^{-1} was achieved in continuous culture, representing a mean doubling time of about 24 hours.

The invention further provides, in a second aspect, a growth medium for culture of mycobacteria, comprising:-

a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
at least 0.1% (v/v) detergent.

The carbon source is preferably selected from glucose, glycerol and an amino acid, and combinations of these carbon sources. The mitogen is present to induce cell division and is preferably asparagine, though other mitogens from inorganic sources are also suitable. Trace elements in the growth medium are preferably selected from Ca, Mg, Zn, Co, Cu, Mn, Fe, K and mixtures thereof, and the nitrogen source is selected from an amino acid and an ammonium salt.

The growth medium optionally further comprises an amino acid component selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glycine, isoleucine, leucine, phenylalanine, serine, and mixtures thereof. The amino acid component can contribute the nitrogen source in the medium.

Other optional components are a vitamin/co-factor component selected from:- inositol, thiamine, calcium pantothenate, co-enzyme A, nicotinamide, biotin, DL-thioctic acid, and mixtures thereof, preferably biotin; and one or more components selected from sodium hydroxide, glutathione, glycerol, haemin, sodium pyruvate and α-ketoglutarate, preferably glycerol and/or pyruvate.

Thus, a particularly preferred embodiment of the invention provides a method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation in the presence of at least 0.1% (v/v) detergent detergent so that a substantially homogenous suspension of single cells is maintained, and in the

presence of a growth medium according to combination of the above-described media.

The mycobacterial culture methods and media of the present invention are suitable for culture of all members of the *Mycobacteria tuberculosis* complex (MTC) as well as mutant and recombinant forms thereof. In one embodiment, the methods and media are used for culture of *M. tuberculosis*, but are also suitable for culture of *M. bovis* and other opportunistic mycobacteria.

According to a third aspect of the present invention there is provided a method of culture of mycobacteriophage, comprising culture of mycobacteria as described above, and contacting said mycobacteria with a mycobacteriophage. In a preferred embodiment, the phage may be added directly to the mycobacterial liquid culture.

Reference to mycobacteriophage includes mutant and recombinant forms thereof.

A mycobacteriophage is any phage which is capable of infecting and replicating in a mycobacterium. The mycobacteriophage need not be specific for the mycobacterium which it infects. However, it may be preferred that the phage exhibits specificity for a given mycobacterial species or even sub-species.

In one embodiment the phage culture method is employed to culture a phage capable of infecting *M. tuberculosis, M. bovis* and/or *M. paratuberculosis*.

The phage culture method is particularly suited to the culture of phage capable of infecting, and which are preferably specific for, *M. tuberculosis*.

In specific embodiments of the present invention, the phage to be cultured is selected from the group consisting of D-34 (Accession No. ATCC 4243-B1), LG (Accession No. ATCC 25618-B1), DS6A (Accession No. ATCC 25618-B2), and D29 (Froman *et al.* 1954).

The preferred mycobacteriophages for use in this aspect of the invention are phages which are capable of causing a lytic infection. This facilitates down-stream phage harvesting.

According to the phage culture method, native or genetically engineered or chemically modified bacteriophage which require susceptible mycobacteria for growth can be generated effectively.

Thus, mycobacteriophage or component parts or phage nucleic acid having prophylactic or therapeutic use, and which may also be used as gene delivery systems in whole or in part, may be grown and manufactured in quantities suitable for clinical and commercial application.

Growth of mycobacteria is performed in a controlled culture system using the culture medium described.

To facilitate phage propagation, the medium may be modified by the incorporation of an agent which is capable of promoting and/or assisting phage adsorption on the mycobacteria cell surface.

Preferred agents include bovine serum albumin and other molecules having cell surface adsorption-promoting properties such as cations. In use, the latter are typically employed at a concentration of approximately 0.015 M.

In one embodiment an agent is incorporated at a final concentration of between 0.01 and 1% w/v, preferably between 0.05% and 0.5% w/v. A typical final concentration is approximately 0.1% w/v.

The agent is preferably added to the mycobacteria culture medium prior to or substantially at the same time as inoculation of the mycobacteriophage.

Since the mycobacteria culture medium of the present invention includes a

detergent, it is preferable to reduce or minimise exposure of the inoculating phage to the detergent because the presence of detergent may have a deleterious effect on phage propagation, possibly through interference with phage adsorption on the mycobacterial cell wall. As mentioned above, the use of an agent may help alleviate potential detergent-related problems.

To this end, a number of method steps are provided for reducing/minimising exposure of the inoculating phage to detergent present in the culture medium. These include:-

(i) reducing the concentration of detergent prior to phage inoculation. This may be achieved by, for example, arresting agitation of the mycobacteria culture medium to allow the mycobacteria to settle by gravity, whereafter detergent-containing medium may be removed from towards the top of the culture vessel and replaced by detergent-free fresh medium;

(ii) as an alternative to (i) fresh detergent-free medium may be added to the culture vessel to dilute the overall detergent concentration; or

(iii) as in (i) above, wherein settling of the bacteria is accelerated by use of a flocculating agent. Following removal of detergent-containing medium and replacement with detergent-free fresh medium, an anti-flocculating agent may be added to reverse/neutralise the effects of the flocculating agent.

In a preferred embodiment, subsequent to phage inoculation and following a sufficient time period to allow phage infection to be established, the detergent concentration of the medium may be increased, for example to substantially the same concentration as prior to phage inoculation, thereby providing optimal mycobacterial growth conditions once again.

For phage propagation, the infectious phage seed culture (ie. inoculum) is typically prepared from seed bank stocks stored at high tighter suspension (eg.

10^9-10^{10} pfu/ml^{-1}) in, for example, phosphate buffer saline solution at -20°C.

Infectious phage seed culture may take the form of purified, semi-purified phage, or a mixture of phage and phage-infected mycobacteria which has been generated in, for example, shake flasks or smaller culture vessels.

The time of phage seed inoculation may vary according to the mycobacterium, medium, phage, and the multiplicity of infectious dose (MOI) employed. Typically, the MOI is in the range of one phage to 10 mycobacteria, but may be varied in accordance with the system employed.

Phage inoculation may occur at any point during the mycobacterial growth cycle. Preferably, inoculation occurs approximately 25-35 hours following initiation of bacterial logarithmic growth. Typically, inoculation occurs 30 hours following initiation of bacterial logarithmic growth.

Culture conditions are preferably monitored and maintained for a further 24 hour period to allow the desired number of bacteriophage replication cycles to occur.

Purification of phage may be achieved using conventional chromatography methods, such as immunoaffinity purification for phage which has been engineered to express an appropriate ligand, or centrifugation of phage from filtered culture supernatant followed by resuspension in an appropriate buffer.

In some instances, infected cells which have yet to undergo phage-induced lysis may be harvested through conventional filtration methods and lysed mechanically or chemically or by ultrasound to release contained phage which may then be further purified as described above.

The present invention is now described with reference to the following specific embodiments, illustrated by drawings in which:-

Fig. 1 shows a schematic view of continuous culture apparatus according to the invention;

Fig. 2 shows a graph of optical density at 540 before and after initiation of continuous culture;

Fig. 3 shows viable *M. tuberculosis* in guinea pig lungs following aerosol challenge with bacteria grown using the medium of the invention; and

Fig. 4 shows viable *M. tuberculosis* in guinea pig spleens following aerosol challenge with bacteria grown using the medium of the invention.

Referring to Fig. 1, a medium reservoir 1 is attached via medium addition pump and line 2 to culture vessel 6. The glass culture vessel 6 comprises a titanium top plate through which are connected temperature probe 7, oxygen electrode 8, air inlet and sparger 9, vent 10, pH electrode 11, alkali addition line 12 and acid addition line 13. Samples of the content of the culture vessel may be taken through sample port 14 and effluent from the culture vessel drains into or is pumped into effluent reservoir 15. The remaining features in Fig. 1 are: a magnetic stirrer unit 3; a heating pad 4; and a magnetic bar 5.

This continuous culture apparatus is used for continuous culture of mycobacteria as described in examples below.

Fig. 2 illustrates the continuous culture of *M. tuberculosis*. After inoculation, the culture was operated in batch for 4 days. Medium addition was then initiated in fed-batch mode. Continuous medium addition was started at 300 h.

Fig. 3 illustrates the viable *M. tuberculosis* in guinea pig lungs following aerosol challenge (error bars + standard deviation are shown) and compares the influence of culture mode on the virulence of *M. tuberculosis*. The virulence of chemostat grown cells was compared with cells grown to mid-exponential batch

phase in ABCD ModTB medium and on Middlebrook agar. Guinea pig challenge with plate-grown cells produced a classical disease process with exponential multiplication in guinea pig lungs up to three weeks post-infection, when lung counts reached 10^6 to 10^7 c.f.u. per lung. After 3 weeks the lung counts declined marginally. Low numbers of bacilli were detected in spleen tissues 2 weeks post-infection followed by an exponential increase up to day 21. Infection with both batch and chemostat grown cells produced a comparable disease process demonstrating that culture virulence was retained.

Fig. 4 illustrates viable *M. tuberculosis* in guinea pig spleens following aerosol challenge as in Fig. 3 (error bars + standard deviation are shown).

Example 1

Materials and Methods

Strain

Studies was performed with *M. tuberculosis* strain H37Rv (NCTC cat. no. 7416) - a representative strain of *M.tuberculosis*. Stock cultures were grown on Middlebrook 7H10 + OADC for 3 weeks at 37 ± 2°C harvested and stored at -70°C as a dense suspension in deionised water.

Culture Medium

A chemically defined culture medium was developed, and was designated CAMR Mycobacterial Medium (see Appendix 1 below). The medium was prepared with high quality water from a Millepore water purification system and filter sterilised by passage through a 0.07 μm pore size cellulose acetate membrane filter capsule (Sartorius Ltd). Middlebrook 7H10 + OADC agar was used to prepare inoculum cultures, enumerate the number of culturable bacteria in chemostat samples, and to assess culture purity.

Culture apparatus

Culture experiments were performed in a one litre glass vessel operated at a

working volume of 500 ml. The culture was agitated by a magnetic bar placed in the culture vessel coupled to a magnetic stirrer positioned beneath the vessel. Culture conditions were continuously monitored and controlled by an Anglicon Microlab Fermentation System (Brighton Systems, Newhaven), linked to sensor probes inserted into the culture through sealed ports in the top plate. The oxygen concentration was monitored with a galvanic oxygen electrode (Uniprobe, Cardiff) and was controlled through feedback control of the agitation rate. Temperature was monitored by an Anglicon temperature probe, and maintained by a heating pad positioned beneath the culture vessel. Culture pH was measured using an Ingold pH electrode (Mettler-Toledo, Leicester) and controlled by automatic addition of either sodium hydroxide (0.5 M) or sulphuric acid (0.5 M). For continuous culture, the culture system was operated by controlling nutrient addition from the medium reservoir and a constant culture volume was maintained by an overflow tube fitted to the side of the vessel.

Inoculation and culture

The vessel was filled with 350 ml of sterile culture medium and parameters were allowed to stabilise at 37°C ± 2°C, pH 6.9 ± 0.2 and a dissolved oxygen tension of approximately 70% air saturation. A dense inoculum suspension was prepared by resuspending Middlebrook agar cultures, grown at 37±2°C for 3 week, in sterile deionised water. The inoculum was aseptically transferred to the culture vessel, to provide an initial culture turbidity of approximately 0.25 at 540 nm. After inoculation the culture was allowed to establish for approximately 50 h. As the culture entered exponential growth, a further 100 ml medium was added and batch growth was monitored by optical density and viable count determination.

For continuous culture, the culture was inoculated and allowed to establish for approximately 50 h as detailed. The culture was then operated in fed batch mode for 48 h with medium addition (approx. 100 ml) as the culture entered exponential growth and 24 h later. Continuous culture was then initiated at a dilution rate of 0.03 h^{-1} [equivalent to a mean generation time (MGT) of 24 h]. Culture parameters were maintained at a dissolved oxygen tension of 50 % (v/v) air

saturation at 37±2°C and pH 6.9 ± 0.2. Growth was monitored by optical density, dry weight and viable count determination.

Culture analyses

The optical density of culture samples was recorded at 540 nm (OD_{540}) in a UV-260 spectrophotometer (Pye Unicam) against a water reference. Culture biomass was determined by dry weight analysis. Samples were treated with 4% (v/v) formaldehyde for at least 24 h and filtered through a pre-dried, pre-weighed, 0.45 μm pore sized, nylon membrane filter (Gelman Sciences), under vacuum. The membrane was rinsed with 10 ml of deionised water, before re-drying to a constant weight, and re-weighing.

Total viable counts were performed by preparing a 10-fold dilution series of the sample in sterile deionised water, and plating 100μl aliquots of appropriate dilutions onto Middlebrook 7H10 plates in triplicate. The plates were incubated at 37°C for 3 weeks before enumerating the number of colonies formed. Culture purity was checked by plating neat samples onto Middlebrook 7H10 and Blood agar and incubating at 37°C.

Results

Batch culture

Growth of *M. tuberculosis* strain H37Rv was established in CAMR Mycobacteria Medium supplemented with 0.2% Tween® 80. After inoculation the culture followed typical batch growth kinetics with a lag phase of approximately 50 hours before entering exponential growth. A minimum doubling time of approximately 14 h was recorded. Cultures were predominantly single cell suspensions.

Continuous culture

Steady-state growth, at a MGT of 24 h, was normally reached 10 days after initiation of continuous culture. Cultures were dense suspensions containing approximately 5×10^8 cfu ml^{-1} and a biomass yield of approximately 1.2 gl^{-1} cell dry weight. Cells were short rods 2 to 3 μm long with occasional clumps of up to

20 cells. Glycerol, the principal carbon source was not depleted during steady state growth, with a residual concentration of 1.25 gl^{-1}. Tween® 80 was present in an amount of 0.1% and enabled the growth of *M. tuberculosis* in a homogeneous suspension made up substantially of single cells at a growth rate conducive to chemostat culture. Cultures grown in the absence of Tween® 80 formed large clumps and surface pellicles and continuous culture was not possible.

Other observations made during operation of this culture indicate that for long-term continuous production it may be necessary to clean the vessel or preferably transfer to a clean vessel at regular intervals, say every 5-6 weeks. Mycobacteria can sometimes tend to attach to the vessel wall, impeding continuous culture, and we have also found, separately, that lowering the oxygen tension to at least 20% air saturation assists to counter this problem.

Influence of culture mode on virulence

The virulence of batch and chemostat grown cells was compared with cells grown on Middlebrook agar. Guinea pigs challenged with plate-grown cells produced a classical disease process with exponential multiplication in guinea pig lungs up to three weeks post infection, when lung counts reached 10^6 to 10^7 c.f.u. per lung (fig. 3). Low numbers of bacilli were detected in spleen tissues 2 weeks post-infection followed by an exponential increase up to day 21, after which growth rate declined (fig. 4). Infection with both batch and chemostat grown cells produced a comparable disease process demonstrating that culture virulence was retained.

The invention thus provides methods for batch and continuous culture of dispersed mycobacteria in high yield and without loss of virulence, and also provides a growth medium therefor. In cultures of the invention, large-scale and consistent production of vaccine components is enabled, for manufacture eg. of bacterial subunits, whole bacilli for vaccine uses and whole bacilli for immune therapies.

Example 2

Production of Mycobacteriophage

Bacteriophage:

Mycobacteriophage e.g. D-34 (Accession No. ATCC 4243-B1) is specific for *M. tuberculosis*. Stock bacteriophage is prepared from liquid culture or soft agar overlay and is stored as a high titre suspension 10^9 - 10^{10} pfu ml^{-1} in PBS at -20°C.

Growth of *M. tuberculosis* and bacteriophage propagation:

Growth of *M. tuberculosis* strain H37Rv is performed in the controlled culture system using the CAMR Mycobacterium Medium as detailed previously in Example 1.

For phage propagation, the CAMR Mycobacterium Medium is modified by the incorporation of 0.1% (w/v) bovine serum albumin (BSA). After inoculation, the culture is allowed to establish and turbidity at 540 nm is monitored to determine the onset of exponential growth. Stock bacteriophage suspension is slowly thawed and added to the culture 30 h after the initiation of logarithmic growth.

A multiplicity of infection of 1 phage to 10 bacilli is used. Culture conditions are continuously monitored and maintained for a further 24 h or until two cycles of phage propagation have occurred. Bacteriophage replication can be followed by monitoring the change in culture turbidity and oxygen utilisation.

The culture is pelleted by centrifugation at 10,000 g for 15 min and the supernatant containing the bacteriophage is retained. The bacteriophage is concentrated by ultrafiltration, washed with phosphate buffered saline and filter sterilized by passage through a 0.45μm cellulose acetate membrane filter. The titre of the concentrated bacteriophage suspension is determined against *M. tuberculosis* using the conventional soft overlay method.

References

Lowrie, D.B., Arber, V.R., and Jackett, P.S. (1979). Phagosome-lysosome fusion and cyclic adenosine 3:5-monophosphate in macrophages infected with *Mycobacterium microti*, *Mycobacterium bovis* BCG and *Mycobacterium leraemurium*. J. Gen. Micro. 110:431-441.

Ratledge, C. (1983). Nutrition, growth and metabolism. p 185-271. In: Ratledge, C., and J. Stanford (eds.), The biology of mycobacteria: immunological and environmental aspects. Acad Press.

Wayne, L.G. (1977). Synchronised replication of *Mycobacterium tuberculosis*. Infect. Immun. 17:528-530.

Wayne, L.G. (1997). Cultivation of Mycobacterium tuberculosis for Research Purposes. In. B R Bloom (ed), Tuberculosis: pathogenesis, protection & control. ASM Press.

Froman, S., Will, D.W, and Bogen, E. (1954). Bacteriophage active against virulent M. tuberculosis. (I) Isolation and Activity. American J. of Public Health, vol. 44, pp 1326-1333.

Appendix 1

Composition of CAMR MYCOBACTERIA MEDIUM

Stock solutions.	mg l^{-1}	Stock Solutions	mg l^{-1}
		Amino acids	
L- alanine	100	L-leucine	100
L-arginine	100	L-lysine	100
L-asparagine	2000	L-methionine	100
L-aspartic acid	100	L-phenylalanine	100
L-cysteine	500	L-proline	100
L-glutamine	100	L-serine	100
L-glutamic acid	100	L-threonine	100
L-glycine	100	L-tryptophan	100
L-histidine HCl	100	L-tyrosine	50
L-isoleucine	100	L-valine	100
		Inorganic salts	
$CaCl_2 . 2H_2O$	0.55	$NaMO_4 \cdot 2H_2O$	1.2
$MgSO_4 . 7H_2O$	214	$NiSO_4 \cdot 6H_2O$	0.53
NH_4VO_3	1.2	$FeSO_4 \cdot 7H_2O$	10
$ZnSO_4 \cdot 7 H_2O$	28.75	KH_2PO_4	220
$CoCl_2 \cdot 6H_2O$	0.48	Na_2SO_4	150
$CuSO_4 \cdot 5H_2O$	0.025	KOH	56
$MnCl_2 \cdot 4H_2O$	0.02		
		Vitamins and co-factors	
inositol	2	nicotinamide	1
thiamine HCl	2	biotin	0.1
calcium -pantothenate	2	DL-thioctic acid	0.1
coenzyme A	0.1		
		Other	
ACES buffer	10000	haemin	2.0
$NaHCO_3$	42	sodium pyruvate	1000
glutathione (reduced)	500	α-ketoglutarate	1000
glycerol	2 ml	Tween® 80	2.0 ml

Stock solution formulations.

(CAMR MYCOBACTERIA MEDIUM).

Stock solutions.	g l^{-1}	mg l^{-1}	Stock Solutions	g l^{-1}	mg l^{-1}
Solution 2.			Solution 6.		
$CaCl_2 . 2H_2O$		55.5	sodium pyruvate	100	
$MgSO_4 . 7H_2O$	21.4				
NH_4VO_3		117	Solution 7.		
$ZnSO_4 \cdot 7 H_2O$	2.875		α-ketoglutarate	100	
Solution 3.			Solution 8.		
$CoCl_2 \cdot 6H_2O$		47.6	inositol		200
$CuSO_4 \cdot 5H_2O$		2.5	thiamine HCl		200
$MnCl_2 \cdot 4H_2O$		2.0	calcium -		
$NaMO_4 \cdot 2H_2O$		121	pantothenate		200
$NiSO_4 \cdot 6H_2O$		52.6	nicotinamide		100
conc. HCl		0.5 ml	biotin		10
Solution 4.			Solution 9.		
$FeSO_4 \cdot 7H_2O$	1.0		DL-thioctic acid	1.0	
Conc. HCl		0.5 ml	ethanol		950 ml
Solution 5.			Solution 10.		
L- alanine	1.0		coenzyme A	1.0	
L-arginine	1.0				
L-asparagine	20.0		Solution 11.		
L-aspartic acid	1.0		haemin	2.0	
L-glutamine	1.0		KOH	56	
L-glutamic acid	1.0				
L-glycine	1.0				
L-histidine HCl	1.0				
L-isoleucine	1.0				
L-leucine	1.0				
L-lysine	1.0				
L-methionine	1.0				
L-phenylalanine	1.0				
L-proline	1.0				
L-serine	1.0				
L-threonine	1.0				
L-tryptophan	1.0				
L-valine	1.0				

All solutions were prepared with high quality Millepore water.

Preparation of CAMR MYCOBACTERIA MEDIUM.

Solution	Quantity
ACES buffer	10.0 g
KH_2PO_4	0.22 g
Na_2SO_4	0.15 g
Millepore water	500 ml
Solution 2	10 ml
Solution 3	10 ml
Solution 5	100 ml
Solution 6	10 ml
Solution 7	10 ml
Solution 8	10 ml
Solution 9	0.1 ml
Solution 10	0.1 ml
L-cysteine HCl	0.5 g
Glutathione (reduced)	0.5 g
L-tyrosine	0.05 g
$NaHCO_3$	0.042 g
Glycerol	0.2 ml
Solution 4	10 ml
Adjust pH to 6.5 with 20% KOH	
Solution 11	1 ml
Tween® 80	2.0 ml
Millepore water up to 1 litre	

Filter sterilise by passage through 0.07 μm filter (Sartorius Ltd.)

The above CAMR medium has been refined and non-essential components omitted as below:-

Composition of CAMR Mycobacterium Medium

Chemical	g l^{-1}	Chemical	mg l^{-1}
L- alanine	0.1	$CaCl_2 . 2H_2O$	0.55
L-arginine	0.1	$MgSO_4 . 7H_2O$	214
L-asparagine	2.0	$ZnSO_4 \cdot 7 H_2O$	28.75
L-aspartic acid	0.1	$CoCl_2 \cdot 6H_2O$	0.48
L-glutamic acid	0.1	$CuSO_4 \cdot 5H_2O$	0.025
L-glycine	0.1	$MnCl_2 \cdot 4H_2O$	0.02
L-isoleucine	0.1	$FeSO_4 \cdot 7H_2O$	10
L-leucine	0.1	KH_2PO_4	222
L-serine	0.1	$NaHCO_3$	42
L-phenylalanine	0.1		
Sodium pyruvate	1.0	Biotin	0.1
ACES buffer	10	Glycerol	2.0 ml
Tween® 80	2.0		

ACES buffer = N-[Carbamoylmethyl]-2-aminoethanesulfonic acid

Stock solution formulations

Stock solutions.	g l^{-1}	mg l^{-1}
Solution 1.		
$CaCl_2 . 2H_2O$		55.5
$MgSO_4 . 7H_2O$	21.4	
$ZnSO_4 \cdot 7 H_2O$	2.875	
Solution 2		
$CoCl_2 \cdot 6H_2O$		47.6
$CuSO_4 \cdot 5H_2O$		2.5
$MnCl_2 \cdot 4H_2O$		2.0
conc. HCl		0.5 ml
Solution 3		
L- alanine	1.0	
L-arginine	1.0	
L-asparagine	20.0	
L-aspartic acid	1.0	
L-glutamic acid	1.0	
L-glycine	1.0	
L-isoleucine	1.0	
L-leucine	1.0	
L-phenylalanine	1.0	
L-serine	1.0	
Solution 4.		
sodium pyruvate	100	
Solution 5.		
$FeSO_4 \cdot 7H_2O$	1.0	
Conc. HCl		0.5 ml
Solution 6		
Biotin		10

All solutions were prepared with high quality Millipore water.

Preparation of CAMR MYCOBACTERIA MEDIUM.

Solution	Quantity
ACES buffer	10.0 g
KH_2PO_4	0.22 g
Millipore water	500 ml
Solution 1	10 ml
Solution 2	10 ml
Solution 3	100 ml
Solution 4	10 ml
Solution 6	10 ml
NaHCO3	0.042 g
Glycerol	2 ml
Solution 5	10 ml

Adjust pH to 6.5 with 20% KOH

Tween® 80	2.0 ml

Millipore water up to 1 litre

Filter sterilise by passage through 0.07 μm filter (Sartorius Ltd.)

CLAIMS

1. A method of culture of mycobacteria, comprising culturing said mycobacteria, in batch fermenter culture or continuous culture, with agitation and in the presence of at least 0.1% (v/v) detergent.

2. A method according to Claim 1, comprising culturing the mycobacteria at a temperature of 35°C +/- 10°C.

3. A method according to Claim 1 or 2, comprising maintaining the pH at 6.9 +/- 0.9.

4. A method according to any of Claims 1 to 3, comprising culturing the mycobacteria with an initial dissolved oxygen concentration of at least 1% (v/v) air saturation.

5. A method according to any of Claims 1 to 4, for culture of mycobacteria selected from *M. tuberculosis*, *M. bovis* and *M. vaccae*.

6. A method according to any of Claims 1 to 5 for batch culture of mycobacteria, wherein detergent is present at from 0.1 to 1.0 % (v/v).

7. A method according to Claim 6, wherein detergent is present at about 0.2 % (v/v).

8. A method according to any of Claims 1 to 5 for continuous culture of mycobacteria.

9. A method according to Claim 8, wherein detergent is present at at least 0.15 % (v/v).

10. A method according to Claim 8 or 9, wherein the culture is carried out continuously with a dilution rate of at least 0.02 h^{-1}.

11. A method according to Claim 10, wherein the culture is carried out continuously with a dilution rate of at least 0.025 h^{-1}.

12. A method according to Claim 8 or 9, comprising growing said mycobacteria in continuous culture, at a temperature of 35°C +/- 10°C, at a dissolved oxygen tension of at least 1 percent, at a pH of 6.9 +/- 0.9, at a dilution rate of at least 0.02 h^{-1}.

13. A growth medium for culture of mycobacteria, comprising:-
a carbon source;
a mitogen;
trace elements comprising at least Mg, K, P and S;
a nitrogen source; and
at least 0.1% (v/v) detergent.

14. A growth medium according to Claim 13, wherein the carbon source is selected from glucose, glycerol and an amino acid.

15. A growth medium according to Claim 13 or 14, wherein the mitogen is asparagine.

16. A growth medium according to any of Claims 13 to 15, comprising trace

elements selected from Ca, Mg, Zn, Co, Cu, Mn, Fe, K, and mixtures thereof.

17. A growth medium according to any of Claims 13 to 16, wherein the nitrogen source is selected from an amino acid and an ammonium salt.

18. A growth medium according to Claim 17, comprising an amino acid component selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glycine, isoleucine, leucine, phenylalanine, serine and mixtures thereof.

19. A growth medium according to any of Claims 13 to 18, further comprising a vitamin/co-factor component selected from inositol, thiamine, calcium pantothenate, co-enzyme A, nicotinamide, biotin, DL-thioctic acid, and mixtures thereof.

20. A medium according to any of Claims 13 to 19, further comprising one or more components selected from sodium hydroxide, glutathione, glycerol, haemin, sodium pyruvate and α-ketoglutarate.

21. A method according to any of Claims 1-12, comprising culturing said mycobacteria in the presence of a growth medium according to any of Claims 13 to 20.

22. A method of culture of mycobacteria substantially as hereinbefore described with reference to the examples.

23. A growth medium substantially as hereinbefore described with reference to the examples.

24. A method of culture of a mycobacteriophage, comprising culture of mycobacteria according to any of Claims 1-12, 21 or 22, and contacting said mycobacteria with a mycobacteriophage.

25. A method according to Claim 24, comprising challenging the mycobacteria with an agent for promoting and/or assisting mycobacteriophage adsorption on the mycobacteria.

26. A method according to Claim 24, wherein challenge occurs prior to or substantially at the same time as contacting the mycobacteria with the mycobacteriophage.

27. A method according to any of Claims 24-26, comprising reducing or minimising exposure of the phage to detergent present in the mycobacteria culture medium.

28. A method according to Claim 27, comprising allowing a phage infection to be established, and increasing the detergent concentration to at least 0.1% (v/v) detergent.



FIG. 1


Continuous culture of M. tuberculosis
Optical density at 540 nm
0
1
2
3
4
5
0
200
400
600
800
Time (h)
continuous culture initiated

FIG. 2


7.5
7
6.5
6
5.5
5
4.5
4
Log10 cfu. lung-1
10
15
20
25
30
Days post infection
Plate
Chemostat
Batch

FIG. 3



FIG. 4

Please type a plus sign inside this box ☐ PTO/SB/01 (12/97) Approved for use through 09/30/00, OMB 0651-0032

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

Attorney Docket Number	18872.0107
First Named Inventor	James, et al.
COMPLETE IF KNOWN	
Application Number	09/914,659
Filing Date	August 31, 2001
Group Art Unit	
Examiner Name	

☐ Declaration Submitted with Initial Filing **OR** ■ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16(e)) required)

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CULTURE OF MYCOBACTERIA

(Title of the Invention)

the specification of which
☐ is attached hereto
OR
■ was filed on (MM/DD/YYYY) 08/31/2001 as United States Application Number or PCT International Application Number 09/914,659 and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application (Numbers)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES	NO
PCT/GB00/00760	PCT	03/02/2000	☐	☐	■
9904773.0	GB	03/02/1999	☐	☐	■
			☐	☐	☐
			☐	☐	☐

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
		☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

DECLARATION – Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number
OR
■ Registered practitioner's name/registration number listed below

Place Customer Number Bar Code Label Here

Name	Registration Number	Name	Registration Number
Ranjana Kadle	40,041	R. Kent Roberts	40,786
John M. Del Vecchio	42,475	Michael F. Scalise	34,920
Martin G. Linihan	24,926	Patrick J. Tracy	42,187
Kevin D. McCarthy	35,278	Daniel C. Oliverio	33,435
David L. Principe	39,336	Edwin T. Bean, Jr.	16,639

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto

Direct all correspondence to: ☐ Customer Number or Bar Code Label *OR* ■ Correspondence address below

Name	Ranjana Kadle				
Address	Hodgson Russ LLP				
Address	One M&T Plaza, Suite 2000				
City	Buffalo	**State**	New York	**ZIP**	14203-2391
Country	United States	**Telephone**	(716) 856-4000	**Fax**	(716) 849-0349

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])	Family Name or Surname
Brian William	James

Inventor's Signature						**Date**	12 December 2001
Residence: City	Salisbury	**State**	Wiltshire	**Country**	GB GBX	**Citizenship**	GB
Post Office Address	5 Lower Road, Lower Bemerton						
Post Office Address							
City	Salisbury	**State**	Wiltshire	**ZIP**	SP2 9NB	**Country**	GB

■ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

DECLARATION	ADDITIONAL INVENTOR(S) **Supplemental Sheet** Page 3of 3

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
2 W Philip			Marsh				
Inventor's Signature	PDMarsh					**Date**	12 December 2001
Residence: City	Salisbury	**State**	Wiltshire	**Country**	GB GBX	**Citizenship**	GB
Post Office Address	Jasmine, Mill Lane, Winterslow						
Post Office Address							
City	Salisbury	**State**	Wiltshire	**ZIP**	SP5 1PR	**Country**	GB

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
3 W James			Chadwick				
Inventor's Signature	Jim Chadwick					**Date**	12 December 2001
Residence: City	Salisbury	**State**	Wiltshire	**Country**	GB GBX	**Citizenship**	GB
Post Office Address	Moon Cottage, Teffont Magna						
Post Office Address							
City	Salisbury	**State**	Wiltshire	**ZIP**	SP3 5QY	**Country**	GB

Name of Additional Joint Inventor, if any:	☐ A petition has been filed for this unsigned inventor						
Given Name (first and middle [if any])			Family Name or Surname				
Inventor's Signature						**Date**	
Residence: City		**State**		**Country**		**Citizenship**	
Post Office Address							
Post Office Address							
City		**State**		**ZIP**		**Country**	

+

SCANNED, #4

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s)_____ of Abstract _____ were not present for scanning.
(Document title)

☐ Page(s)_____ of _____ were not present for scanning.
(Document title)

☐ ***Scanned copy is best available.***